S-1 induced secondary acute erythroid leukemia with a chromosome inv(12)(p13;q13)

Table 1 Therapy-related leukemia cases induced by (adjuvant therapy constituted) mainly of pyrimidine anti-metabolites

No.	Age/sex	Primary tumor	Type of treatment for(primary) tumor	Duration from prior therapy (mo)	FAB	Karyotype	Survival duration (mo)	Ref.
1	81/M	Colon	c.r+ 1086 g tegafur/uracil	24	M4	47XY, +8, t(11;17)(q23;q25)	14	[10]
2	54/M	Colon	c.r+ 315 g of UFT +210 mg of MMC	40	M6	44, XY, dic(5;17)(q13;p11), -7, add (15)(q24) 44, as above, -dic(5;17), +mar1	3 >	[11]
3	67/M	Colon rectum	c.r+ 645 g of tegafur, 560 mg of Ara-C, 56 mg of MMC	96	M2	45XY, -5, -6, 7q-, -8, -20, +3mar	6	[9]
4	67/M	Colon	c.r+ 252g of UFT, 80mg of MMC	108	M2	47XY, +1, der(1;7)(q10,p10), -7, +8	10	[9]

c.r: Curative resection; M: Male; UFT: Tegafur/uracil; MMC: Mitomycin C; Ara-C: Cytarabine; FAB: French-American-British classification.